Laura Fugazzola
Laura Fugazzola
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Dagmar Fuhrer
Dagmar Fuhrer
Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Barbara Jarzab
Barbara Jarzab
Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Sophie Leboulleux
Sophie Leboulleux
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Kate Newbold
Kate Newbold
Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Jan Smit
Jan Smit
Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Jan Smit in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
years, many new drugs have been investigated for the treatment of progressive RAI-R TC. Currently, 2 multikinase inhibitors (MKI) have been approved for treatment by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), e
Daniela Dias
Daniela Dias
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Inês Damásio
Inês Damásio
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Pedro Marques
Pedro Marques
Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisbon, Portugal
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Helder Simões
Helder Simões
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Helder Simões in
Google Scholar
PubMed
Search for other papers by Helder Simões in
Google Scholar
PubMed
Ricardo Rodrigues
Ricardo Rodrigues
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Branca Maria Cavaco
Branca Maria Cavaco
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Valeriano Leite
Valeriano Leite
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
developed for advanced thyroid carcinoma. Multikinase inhibitors have a non-negligible toxicity that may decrease the patient’s quality of life. Novel insights GEMOX (gemcitabine plus oxaliplatin) may have a role in patients with
Carla Gambale
Carla Gambale
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Alessandro Prete
Alessandro Prete
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Chiara Romei
Chiara Romei
Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Alessandro Celi
Alessandro Celi
Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Antonio Matrone
Antonio Matrone
Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
advanced/metastatic ( 1 ). According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of
Elisa Minaldi
Elisa Minaldi
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Virginia Cappagli
Virginia Cappagli
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Loredana Lorusso
Loredana Lorusso
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Laura Valerio
Laura Valerio
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Carlotta Giani
Carlotta Giani
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Matilde Viglione
Matilde Viglione
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Laura Agate
Laura Agate
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Eleonora Molinaro
Eleonora Molinaro
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Antonio Matrone
Antonio Matrone
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
, interquartile range; MKI, multikinase inhibitors; TC, thyroid carcinoma. Sorafenib The group treated with sorafenib was represented by 74 patients, of which 40/74 (54.1%) were females and 34/74 (45.9%) were males. The mean age at the starting of
Tim Brandenburg
Tim Brandenburg
Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Tim Brandenburg in
Google Scholar
PubMed
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Tim Brandenburg in
Google Scholar
PubMed
Philipp Muchalla
Philipp Muchalla
Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Philipp Muchalla in
Google Scholar
PubMed
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Philipp Muchalla in
Google Scholar
PubMed
Sarah Theurer
Sarah Theurer
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
Kurt Werner Schmid
Kurt Werner Schmid
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Kurt Werner Schmid in
Google Scholar
PubMed
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Kurt Werner Schmid in
Google Scholar
PubMed
Dagmar Führer
Dagmar Führer
Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
, the diagnosis of a PSCC of the thyroid was established in the patient. Due to the limited known therapeutic options, we decided to advocate combined BRAF V600E/MEK targeting by multikinase inhibitors (MKI) dabrafenib and trametinib [ 13 ] as an
Stacey A. Fedewa
Stacey A. Fedewa
Surveillance and Health Services Research, American Cancer Society, Atlanta, Ga., USA
Search for other papers by Stacey A. Fedewa in
Google Scholar
PubMed
Search for other papers by Stacey A. Fedewa in
Google Scholar
PubMed
Ahmedin Jemal
Ahmedin Jemal
Surveillance and Health Services Research, American Cancer Society, Atlanta, Ga., USA
Search for other papers by Ahmedin Jemal in
Google Scholar
PubMed
Search for other papers by Ahmedin Jemal in
Google Scholar
PubMed
Amy Y. Chen
Amy Y. Chen
Department of Otolaryngology, Emory University School of Medicine, Atlanta, Ga., USA
Search for other papers by Amy Y. Chen in
Google Scholar
PubMed
Search for other papers by Amy Y. Chen in
Google Scholar
PubMed
Food and Drug Administration (FDA) approved the use of several multikinase inhibitors (MKIs) based on recent clinical trials showing their ability to limit disease progression [ 6 , 7 , 8 , 9 , 10 , 11 ]. It is not known, however, whether the
Ana Piñar-Gutiérrez
Ana Piñar-Gutiérrez
UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España
Search for other papers by Ana Piñar-Gutiérrez in
Google Scholar
PubMed
Search for other papers by Ana Piñar-Gutiérrez in
Google Scholar
PubMed
Ana R Romero-Lluch
Ana R Romero-Lluch
UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España
Search for other papers by Ana R Romero-Lluch in
Google Scholar
PubMed
Search for other papers by Ana R Romero-Lluch in
Google Scholar
PubMed
Suset Dueñas-Disotuar
Suset Dueñas-Disotuar
UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España
Search for other papers by Suset Dueñas-Disotuar in
Google Scholar
PubMed
Search for other papers by Suset Dueñas-Disotuar in
Google Scholar
PubMed
Irene de Lara-Rodríguez
Irene de Lara-Rodríguez
UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España
Search for other papers by Irene de Lara-Rodríguez in
Google Scholar
PubMed
Search for other papers by Irene de Lara-Rodríguez in
Google Scholar
PubMed
María Ángeles Gálvez-Moreno
María Ángeles Gálvez-Moreno
Servicio de Endocrinología, Hospital Universitario Reina Sofía, Córdoba, España
Search for other papers by María Ángeles Gálvez-Moreno in
Google Scholar
PubMed
Search for other papers by María Ángeles Gálvez-Moreno in
Google Scholar
PubMed
Tomás Martín-Hernández
Tomás Martín-Hernández
Servicio de Endocrinología, Hospital Universitario Virgen Macarena, Sevilla, España
Search for other papers by Tomás Martín-Hernández in
Google Scholar
PubMed
Search for other papers by Tomás Martín-Hernández in
Google Scholar
PubMed
Jorge García-Alemán
Jorge García-Alemán
Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, España
Search for other papers by Jorge García-Alemán in
Google Scholar
PubMed
Search for other papers by Jorge García-Alemán in
Google Scholar
PubMed
Guillermo Martínez-de Pinillos
Guillermo Martínez-de Pinillos
Servicio de Endocrinología, Hospital Universitario Virgen de Valme, Sevilla, España
Search for other papers by Guillermo Martínez-de Pinillos in
Google Scholar
PubMed
Search for other papers by Guillermo Martínez-de Pinillos in
Google Scholar
PubMed
Elena Navarro-González
Elena Navarro-González
UGC Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, España
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
Search for other papers by Elena Navarro-González in
Google Scholar
PubMed
/Hematology 2005 56 365 – 378 . ( https://doi.org/10.1016/j.critrevonc.2005.03.011 ) 9 Navarro-Gonzalez E . Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid
Simone De Leo
Simone De Leo
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Carla Colombo
Carla Colombo
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Marta Di Stefano
Marta Di Stefano
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Antonella Dubini
Antonella Dubini
Division of Laboratory Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Antonella Dubini in
Google Scholar
PubMed
Search for other papers by Antonella Dubini in
Google Scholar
PubMed
Silvia Cozzi
Silvia Cozzi
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Silvia Cozzi in
Google Scholar
PubMed
Search for other papers by Silvia Cozzi in
Google Scholar
PubMed
Luca Persani
Luca Persani
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Laura Fugazzola
Laura Fugazzola
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Weight loss is one of the most frequent adverse events during treatment with multikinase inhibitors, but scanty data are available on its extent and characteristics. This is the first assessment of the body composition by bioelectrical impedance analysis and of circulating leptin and ghrelin levels, in patients with advanced thyroid cancer before and at regular intervals during treatment with the tyrosine kinase inhibitor lenvatinib. Body mass index (BMI) decreased in all patients, with an average ∆ reduction of –6.4, –9.8, and –15.3% at 3, 6, and 12 months of treatment, respectively. Interestingly, in most patients, after the first year of treatment, BMI remained stable. In all patients, fat mass (FM) reduced more than fat-free mass, the highest decrement being of –60 and –16%, respectively. A decrease in the body cell mass, a parameter mainly due to muscle tissue, was observed only in patients with a vast baseline muscular mass. Total body water decreased in parallel to BMI. During treatment, leptin tightly paralleled the decrease of BMI values, consistent with the decrease in FM, whereas ghrelin levels increased upon BMI decrease. The loss of the FM accounts for the largest portion of BMI reduction during lenvatinib treatment. The increase in ghrelin could account for the BMI stabilization observed after 1 year of treatment. Nevertheless, oral nutritional supplements should be given as early as possible and athletic patients should be encouraged to maintain physical activity. In some circumstances, parenteral nutrition is required for the rehabilitation of these patients.
Carla Colombo
Carla Colombo
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Daniele Ceruti
Daniele Ceruti
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Simone De Leo
Simone De Leo
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Grzegorz Bilo
Grzegorz Bilo
Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Matteo Trevisan
Matteo Trevisan
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Noemi Giancola
Noemi Giancola
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Claudia Moneta
Claudia Moneta
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Gianfranco Parati
Gianfranco Parati
Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Luca Persani
Luca Persani
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Laura Fugazzola
Laura Fugazzola
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Introduction Multikinase inhibitors (MKIs) with strong anti-angiogenetic action are frequently used for the treatment of advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) or medullary thyroid cancers (MTCs) ( 1 , 2
Zoe A. Efstathiadou
Zoe A. Efstathiadou
Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Charalambos Tsentidis
Charalambos Tsentidis
Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Alexandra Bargiota
Alexandra Bargiota
Department of Endocrinology, University of Thessaly, Larisa, Greece
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Vasiliki Daraki
Vasiliki Daraki
Department of Endocrinology, University Hospital of Crete, Heraklion, Greece
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Kalliopi Kotsa
Kalliopi Kotsa
Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Georgia Ntali
Georgia Ntali
Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Labrini Papanastasiou
Labrini Papanastasiou
Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Stelios Tigas
Stelios Tigas
Department of Endocrinology, University of Ioannina, Ioannina, Greece
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Konstantinos Toulis
Konstantinos Toulis
Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Kalliopi Pazaitou-Panayiotou
Kalliopi Pazaitou-Panayiotou
Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Maria Alevizaki
Maria Alevizaki
Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
part was formed as follows: (“tyrosine kinase inhibitors” OR” tyrosine kinase inhibitor” OR tki OR tkis OR “Multikinase inhibitors” OR “Multikinase inhibitor” OR “Protein Kinase Inhibitors” OR afatinib OR alectinib OR axitinib OR bosutinib OR
